268 filings
8-K
LRMR
Larimar Therapeutics Inc
10 Jun 24
Other Events
6:05am
8-K
LRMR
Larimar Therapeutics Inc
31 May 24
Submission of Matters to a Vote of Security Holders
4:07pm
8-K
LRMR
Larimar Therapeutics Inc
30 May 24
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
4:08pm
EFFECT
LRMR
Larimar Therapeutics Inc
28 May 24
Notice of effectiveness
12:15am
8-K
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
8-K
cmq82h5lvntxb
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
ARS
yuvv izl5u5v
29 Apr 24
Annual report to shareholders
4:04pm
PRE 14A
28igpmxxxtk3 yqfg3i
12 Apr 24
Preliminary proxy
6:06am
S-8
351he1xo9vd7wyn q0
14 Mar 24
Registration of securities for employees
5:07pm
S-8
hd8nr9 1o0v
14 Mar 24
Registration of securities for employees
5:07pm
8-K
vgplzstjtpor6finfkd
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
8-K
0od3ehhl
11 Mar 24
Other Events
4:09pm
8-K
4lyr35ov25jes
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
424B5
07uyzcbez3s3m
14 Feb 24
Prospectus supplement for primary offering
5:08pm
8-K
yenj4ue
14 Feb 24
Termination of a Material Definitive Agreement
6:06am
424B5
avr7zq5llt3dp
13 Feb 24
Prospectus supplement for primary offering
4:46pm